Portfolio Companies

Long-standing commitment to European mid-market investments

We have supported the European mid-market since 1985, and we have been active investors in each of our three principal markets – UK, France and Germany – as well as in the Nordic and Benelux regions.

We typically invest in high quality international businesses with an enterprise value of between €75 million and €300 million, which we look to back through their next phase of growth, which will typically include a buy & build, roll-out or expansion strategy.

Investments

Sector

Business & Financial Services

Main location

United Kingdom

Investment date

2016

Deal size

N/D

Website

lifetimetraining.co.uk

Silverfleet Capital contact

Adrian Yurkwich

Status

Unrealised

LoadingLoading

Sector

Manufacturing

Main location

United Kingdom

Investment date

2016

Deal size

£65m

Website

sigmacomponents.com

Silverfleet Capital contact

David MacKenzie

Status

Unrealised

LoadingLoading

Sector

Manufacturing

Main location

France

Investment date

2016

Deal size

N/D

Website

coventya.com

Silverfleet Capital contact

Alexandre Lefebvre

Status

Unrealised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

Denmark

Investment date

2015

Deal size

N/D

Website

masai.eu

Silverfleet Capital contact

Gareth Whiley

Status

Unrealised

LoadingLoading

Sector

Business & Financial Services

Main location

Norway

Investment date

2014

Deal size

€195m

Website

agr.com

Silverfleet Capital contact

Adrian Yurkwich

Status

Unrealised

LoadingLoading

Sector

Manufacturing

Main location

Denmark

Investment date

2014

Deal size

N/D

Website

phaseone.com

Silverfleet Capital contact

Gareth Whiley

Status

Unrealised

LoadingLoading

Sector

Business & Financial Services

Main location

Germany

Investment date

2013

Deal size

N/D

Website

yourccc.com

Silverfleet Capital contact

Guido May

Status

Unrealised

LoadingLoading

Sector

Business & Financial Services

Main location

Guernsey

Investment date

2013

Deal size

£50m

Website

ipes.com

Silverfleet Capital contacts

Kay Ashton
Mark Piasecki

Status

Unrealised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

France

Investment date

2012

Deal size

€65m

Website

lafeemaraboutee.fr

Silverfleet Capital contact

Alexandre Lefebvre

Status

Unrealised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

Germany

Investment date

2010

Deal size

N/D

Website

creatrade-holding.de

Silverfleet Capital contact

Guido May

Status

Unrealised

LoadingLoading

Sector

Manufacturing

Main location

Denmark

Investment date

2013

Exit date

2016

Deal size (exit)

€310m

Website

cimbria.com

Status

Realised

LoadingLoading

Sector

Manufacturing

Main location

Germany

Investment date

2009

Exit date

2016

Deal size

N/D

Website

kalle.de

Status

Realised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

United Kingdom

Investment date

2010

Exit date

2015

Deal size (exit)

£256m

Website

office.co.uk

Status

Realised

LoadingLoading

Sector

Healthcare

Main location

United Kingdom

Investment date

2011

Exit date

2014

Deal size (exit)

£230m

Website

aesica-pharma.co.uk

Status

Realised

LoadingLoading

Sector

Healthcare

Main location

Germany

Investment date

2004

Exit date

2011

Deal size (exit)

€170m

Website

mwdental.de

Status

Realised

LoadingLoading

Sector

Healthcare

Main location

United States

Investment date

2004

Exit date

2011

Deal size (exit)

$675m

Website

sterigenics.com

Status

Realised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

France

Investment date

2006

Exit date

2010

Deal size (exit)

€417m

Website

histoiredor.com

Status

Realised

LoadingLoading

Sector

Business & Financial Services

Main location

Benelux

Investment date

2004

Exit date

2008

Deal size (exit)

€750m

Website

tmf-group.com

Status

Realised

LoadingLoading

Sector

Manufacturing

Main location

Germany

Investment date

2005

Exit date

2008

Deal size (acquisition)

€320m

Website

jost-world.com

Status

Realised

LoadingLoading

Sector

Healthcare

Main location

Sweden

Investment date

2004

Exit date

2007

Deal size (exit)

€1.3bn

Website

phadia.com

Status

Realised

Phadia

Business overview

Phadia is the global leading in-vitro allergy diagnostics company, specialising in the development, manufacture and marketing of complete blood systems to support the clinical diagnosis and monitoring of allergy and auto-immune diseases.

Headquartered in Uppsala, Sweden, Phadia has international operations in nineteen locations, supplying over 3,000 laboratories in sixty countries.

Investment rationale

Phadia was a global leader in its niche of allergy diagnostics but within the larger Pfizer group it had demonstrated relatively low growth historically and was not a clear strategic fit with other parts of the group.

Silverfleet Capital has deep sector knowledge in healthcare and specific experience of investing in the diagnostic sub-sector, having owned Oxoid, a supplier to microbiology diagnostic labs. In 2004, we were working with an industry adviser, Iain Ross, who had previously been CEO of Allergy Therapeutics and were convinced that the field of allergy and allergy diagnostics would continue to grow. In particular we believed that we could support Phadia in its ambition to take in vitro allergy diagnostics into the USA, where traditionally allergy testing has been conducted using “skin prick” tests only.

In addition to the market opportunity, in Phadia we saw that there was an opportunity to improve the operational efficiency of the business and reduce costs significantly as a stand-alone entity. The company had also substantially completed a major capital expenditure programme, investing in a next generation of diagnostic equipment to install at its clients’ laboratories; and that with increased cost control and good working capital management, Phadia was set to be extremely cash generative for the next few years.

Value creation

The acquisition itself was a highly complex carve-out from the Pfizer group, involving nineteen simultaneous asset purchases and regulatory filings; however we are very experienced at such transactions.

We helped to build the incumbent management team with a number of additional executive and non-executive appointments to help drive efficiencies and support international growth. With this deeper management resource, the cost efficiency programme was able to be implemented swiftly and resulted in an immediate and substantial profit uplift.

Soon after our investment we invested in a pilot programme in the USA, recruiting sales representatives and demonstrating that the US market was ready for in vitro testing. The business also continued to invest in research and development of a “doctor’s office” allergy test, which obtained FDA approval shortly after our exit.

In 2005 we supported management’s buy and build ambitions, with the acquisition of a key supplier of rare allergens to Phadia in a €44 million deal, which gave the business security of supply and also captured increased margins.

Outcome

Due to Phadia’s strong cash generation, we were able to refinance the business in September 2005, returning 105% of cost to our investors. Subsequently in 2006, with the investment thesis proven, we initiated a dual-track sale process with an auction to trade and private equity purchasers being run alongside a potential flotation of the company.

In January 2007 we completed the sale of the business to Cinven for €1.3 billion resulting in a return of 4.8x cost and a 96% IRR. The deal was awarded Large Deal of the Year 2007 by the BVCA.

Global footprint

Global footprint Global footprint

LoadingLoading

Sector

Manufacturing

Main location

Germany

Investment date

2005

Exit date

2006

Deal size (exit)

€157m

Website

global-safety-textiles.com

Status

Realised

LoadingLoading

Sector

Business & Financial Services

Main location

France

Investment date

1998

Exit date

2006

Deal size (exit)

€117m

Website

group-iph.com

Status

Realised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

United Kingdom

Investment date

2000

Exit date

2005

Deal size (exit)

£262m

Status

Realised

LoadingLoading

Sector

Business & Financial Services

Main location

United Kingdom

Investment date

2000

Exit date

2005

Deal size (exit)

£520m

Website

rrdonnelley.com/gds

Status

Realised

LoadingLoading

Sector

Manufacturing

Main location

Finland

Investment date

1996

Exit date

2005

Deal size (exit)

€345m

Website

kemira.com

Status

Realised

LoadingLoading

Sector

Business & Financial Services

Main location

United Kingdom

Investment date

2000

Exit date

2005

Deal size

N/D

Website

linkfinancial.co.uk

Status

Realised

LoadingLoading

Sector

Healthcare

Main location

United Kingdom

Investment date

2000

Exit date

2004

Deal size (exit)

£177m

Website

oxoid.com

Status

Realised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

United Kingdom

Investment date

2001

Exit date

2003

Deal size (exit)

£150m

Website

oasis-stores.com

Status

Realised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

United Kingdom

Investment date

1997

Exit date

2003

Deal size (exit)

£1.2bn

Website

galabingo.co.uk

Status

Realised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

France

Investment date

1999

Exit date

2002

Deal size (exit)

€402m

Website

joa-casino.com

Status

Realised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

United Kingdom

Investment date

1998

Exit date

2001

Deal size (exit)

£30m

Website

firedearth.com

Status

Realised

LoadingLoading

Sector

Retail, Leisure & Consumer

Main location

United Kingdom

Investment date

1996

Exit date

2000

Deal size (exit)

£499m

Status

Realised

LoadingLoading

We couldn’t find any investments matching your criteria. Please alter your selection above.